41 results on '"Saravia, Diana"'
Search Results
2. Efficacy of chemotherapy in patients with HR+/HER2–Invasive lobular breast cancer
3. Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer
4. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
5. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab
6. Factors Associated with the Decision to Decline Chemotherapy in Metastatic Non-Small Cell Lung Cancer
7. Social disparities in pain management provision in stage IV lung cancer: A national registry analysis
8. Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?
9. Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes
10. Five-year survival stratification using “the Cancer Of the Bladder Risk Assessment” (COBRA) score for micropapillary and sarcomatoid urothelial carcinoma of the bladder variants.
11. Five-year survival comparison of different treatment modalities for muscle invasive urothelial carcinoma, squamous cell carcinoma and adenocarcinoma of the bladder: An analysis of the National Cancer Database.
12. Abstract P1-08-33: Disparities in the practice of precision medicine? Using multi-gene testing in early-stage, HR+/HER2- breast cancer
13. Abstract P2-12-12: The effect of Neoadjuvant Chemotherapy in reducing the need for axillary lymph node dissection in HR+/HER2- node positive breast cancers
14. Abstract P2-07-07: Does OncotypeDX have predictive value in HER2+ breast cancer?
15. Abstract PD14-06: Does chemotherapy benefit patients with HR+/HER2- invasive lobular breast cancer?
16. Abstract P2-12-17: Comparative outcomes of Neoadjuvant versus Adjuvant chemotherapy in HR+/HER2- node positive breast cancer
17. Abstract P4-05-10: Composite score combining multi-gene testing with liquid biopsy may have stronger prognostic value in HR+/HER2- breast cancer
18. Metastasectomy versus radiation of secondary sites in stage IV breast cancer: Analysis from a national cancer registry
19. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
20. Use of brain radiotherapy as part of first course of treatment for NSCLC with de novo brain metastasis.
21. Differential responses to therapy in Hispanic NSCLC patients with EGFR, KRAS, or TP53 mutations.
22. A national analysis of untreated stage III non-small cell lung cancer in black and white patients.
23. Patterns of survival in NSCLC with de novo brain metastasis: SRS, WBRT, and no radiotherapy cohorts.
24. Cancer disparities among patients with advanced metastatic breast cancer.
25. Metastasectomy versus radiation of secondary sites in stage IV breast cancer.
26. Stage migration in breast cancer: Better detection or semantics in staging?
27. Prognostic value of systemic inflammatory markers in first- and subsequent-line immunotherapy and durability of response in NSCLC.
28. A comparative analysis of mortality between black and white stage III non–small cell lung cancer patients in the United States.
29. Impact of STK11 and KRAS co-mutations on outcomes with immunotherapy in non-small cell lung cancer.
30. Concordance of next-generation sequencing between tissue and liquid biopsies in non-small cell lung cancer.
31. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
32. Clinical responses and survival in Hispanic patients with non-small cell lung cancer treated with immunotherapy compared with non-Hispanic whites.
33. Can texture analysis of pre-immunotherapy CT imaging predict clinical outcomes for patients with advanced NSCLC treated with Nivolumab?
34. Neutrophil-lymphocyte-ratio to complement the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
35. High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).
36. P1.01-043 Comparison of Gender, Race Distribution, and Survival in the 1990s to 2010s in Lung Cancer Patients at a Single Institution
37. P3.02c-081 Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
38. Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients
39. Disparities Between Patient and Hematology/Oncology Physician Expectations for Integrative Oncology in an Ethnically Diverse Population
40. Use of Farmers Markets by Mothers of WIC Recipients, Miami-Dade County, Florida, 2011
41. Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.